Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma
The purpose of this study is to assess the safety and effectiveness of the investigational drug abemaciclib in patients with dedifferentiated liposarcoma that came back after therapy or has continued to grow. Abemaciclib is designed to inhibit cancer growth by blocking cyclin-dependent kinases (CDK), enzymes which cancer cells need to grow and divide. It is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic, locally advanced, or inoperable dedifferentiated liposarcoma that came back after therapy or has continued to grow.
- Patients may have had no prior treatment or any number of previous therapies.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Mark A. Dickson at 646-888-4164.